Following terms shared definitions. Some might be same term need to merge, some seems the annotations were added as definitions by mistake.
ID
Definition
VO:0000138
YH
VO:0000945
YH
VO:0001135
live attenuated Brucella vaccine is a live attenuated vaccine that protects against a Brucella melitensis infection.
VO:0001136
live attenuated Brucella vaccine is a live attenuated vaccine that protects against a Brucella melitensis infection.
VO:0003119
Kallan Roan, Oliver He
VO:0003440
Kallan Roan, Oliver He
VO:0007260
An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. Anti-CTLA4 MoAb RNA/GITRL RNA-transfected DC vaccine is prepared by transfecting DCs with RNAs encoding humanized heavy and light chains of the anti-CTLA4 (cytotoxic T-Lymphocyte-Associated Antigen 4) monoclonal antibody and tumor necrosis factor (ligand) superfamily, member 18 (TNFSF18 or GlTRL); expression of anti-CTLA4 blocks the inhibitory effect of CTLA4 on the activation of T-lymphocytes, while expression of GlTRL modulates T lymphocyte survival in peripheral tissues. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses.
VO:0007477
An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. Anti-CTLA4 MoAb RNA/GITRL RNA-transfected DC vaccine is prepared by transfecting DCs with RNAs encoding humanized heavy and light chains of the anti-CTLA4 (cytotoxic T-Lymphocyte-Associated Antigen 4) monoclonal antibody and tumor necrosis factor (ligand) superfamily, member 18 (TNFSF18 or GlTRL); expression of anti-CTLA4 blocks the inhibitory effect of CTLA4 on the activation of T-lymphocytes, while expression of GlTRL modulates T lymphocyte survival in peripheral tissues. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses.
VO:0005361
A water-dispersed liquid nanoparticle combined with an immuno-stimulating compound
VO:0005362
A water-dispersed liquid nanoparticle combined with an immuno-stimulating compound
VO:0001018
A viral vaccine that protects aganist Newcastle disease virus infection.
VO:0001222
A viral vaccine that protects aganist Newcastle disease virus infection.
VO:0000642
A viral vaccine that protects against infection with influenza virus.
VO:0005461
A viral vaccine that protects against infection with influenza virus.
VO:0003044
A viral vaccine against infection of a Lymphocytic choriomeningitis virus.
VO:0003055
A viral vaccine against infection of a Lymphocytic choriomeningitis virus.
VO:0000744
A vaccine that protects against, Diphtheria, Tetanus, Pertussis (whooping cough), Polio, and Haemophilus influenzae type b.
VO:0003177
A vaccine that protects against, Diphtheria, Tetanus, Pertussis (whooping cough), Polio, and Haemophilus influenzae type b.
VO:0001017
A vaccine that protects against Marek's; disease virus.
VO:0012162
A vaccine that protects against Marek's; disease virus.
VO:0000958
A vaccine that protects against Herpes simplex virus type 1 and 2.
VO:0012168
A vaccine that protects against Herpes simplex virus type 1 and 2.
VO:0000137
a vaccine role that indicates the vaccine being a combination vaccine.
VO:0000504
a vaccine role that indicates the vaccine being a combination vaccine.
VO:0005176
A synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2 vaccine
VO:0005394
A synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2 vaccine
VO:0005332
A SARS-CoV-2 RNA vaccine by Arcturus Therapeutics, Inc.
VO:0005347
A SARS-CoV-2 RNA vaccine by Arcturus Therapeutics, Inc.
VO:0005082
A SARS-CoV-2 protein subunit vaccine based on recombinant RBD subunits manufactured by the Center for Genetic Engineering and Biotechnology (CIGB).
VO:0005083
A SARS-CoV-2 protein subunit vaccine based on recombinant RBD subunits manufactured by the Center for Genetic Engineering and Biotechnology (CIGB).
VO:0005165
A SARS-CoV-2 DNA vaccine developed by AnGes.
VO:0005322
A SARS-CoV-2 DNA vaccine developed by AnGes.
VO:0005126
A SARS DNA vaccine made from rDNA-expressed ectodomain of the S protein.
VO:0005149
A SARS DNA vaccine made from rDNA-expressed ectodomain of the S protein.
VO:0005464
A poliovirus vaccine that uses poliovirus particles that have been grown under controlled conditions and then killed to prevent disease caused from the vaccine.
VO:0005465
A poliovirus vaccine that uses poliovirus particles that have been grown under controlled conditions and then killed to prevent disease caused from the vaccine.
VO:0005469
A poliovirus vaccine that uses poliovirus particles that have been grown under controlled conditions and then killed to prevent disease caused from the vaccine.
VO:0010718
A poliovirus vaccine that uses poliovirus particles that have been grown under controlled conditions and then killed to prevent disease caused from the vaccine.
VO:0007395
A multivalent vaccine comprised of the epitope antigens of Globo H hexasaccharide 1 (Globo H), GM2 ganglioside, Lewis-Y, MUC1-32-mer, TF(c), and Tn(c) conjugated with keyhole limpet hemocyanin, with potential antineoplastic activity. The antigens included in this vaccine are associated various cancer cells. Vaccination with this multivalent vaccine may induce production of IgG and IgM antibodies as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumors expressing these antigens.
VO:0007557
A multivalent vaccine comprised of the epitope antigens of Globo H hexasaccharide 1 (Globo H), GM2 ganglioside, Lewis-Y, MUC1-32-mer, TF(c), and Tn(c) conjugated with keyhole limpet hemocyanin, with potential antineoplastic activity. The antigens included in this vaccine are associated various cancer cells. Vaccination with this multivalent vaccine may induce production of IgG and IgM antibodies as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumors expressing these antigens.
VO:0005809
A Live attenuated vaccine that immunizes against Toxoplasma gondii trypmastigote.
VO:0005810
A Live attenuated vaccine that immunizes against Toxoplasma gondii trypmastigote.
VO:0005811
A Live attenuated vaccine that immunizes against Toxoplasma gondii trypmastigote.
VO:0005812
A Live attenuated vaccine that immunizes against Toxoplasma gondii trypmastigote.
VO:0005813
A Live attenuated vaccine that immunizes against Toxoplasma gondii trypmastigote.
VO:0005806
A Live attenuated vaccine that immunizes against Plasmodium falciparum sporozoite.
VO:0005807
A Live attenuated vaccine that immunizes against Plasmodium falciparum sporozoite.
VO:0005808
A Live attenuated vaccine that immunizes against Plasmodium falciparum sporozoite.
VO:0005802
A Live attenuated vaccine that immunizes against Giardi lamblia trophozoite.
VO:0005803
A Live attenuated vaccine that immunizes against Giardi lamblia trophozoite.
VO:0005804
A Live attenuated vaccine that immunizes against Giardi lamblia trophozoite.
VO:0005805
A Live attenuated vaccine that immunizes against Giardi lamblia trophozoite.
VO:0000489
a licensed vaccine role that is bears in a licensed human vaccine.
VO:0000551
a licensed vaccine role that is bears in a licensed human vaccine.
VO:0003168
A combination vaccine that protects against diphtheria, tetanus, pertussis, and Haemophilus influenzae type B.
VO:0003169
A combination vaccine that protects against diphtheria, tetanus, pertussis, and Haemophilus influenzae type B.
VO:0007292
A cell-based vaccine composed of autologous tumor cells fused with Epstein-Barr virus-transformed B-lymphoblastoid cells. Upon administration, this vaccine may stimulate a cytotoxic T cell response against tumor cells, resulting in tumor cell lysis.
VO:0007293
A cell-based vaccine composed of autologous tumor cells fused with Epstein-Barr virus-transformed B-lymphoblastoid cells. Upon administration, this vaccine may stimulate a cytotoxic T cell response against tumor cells, resulting in tumor cell lysis.
VO:0007204
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a recombinant adenoviral vector encoding three full length human melanoma associated antigens (MAAs), tyrosinase, melan-A (MART-1) and the melanoma antigen A6 (MAGEA6), with potential antineoplastic activity. Upon intradermal administration, adenovirus encoding tyrosinase/MART-1/MAGEA6-transduced autologous DC vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tyrosinase/MART-1/MAGEA6-positive tumor cells, which may result in tumor cell death and decreased tumor growth. Tyrosinase, a melanoma-specific differentiation antigen, catalyzes the first step of melanin synthesis in melanocytes. Vaccination with multi-antigen modified DC may improve the efficacy of the DC immunotherapy.
VO:0007205
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a recombinant adenoviral vector encoding three full length human melanoma associated antigens (MAAs), tyrosinase, melan-A (MART-1) and the melanoma antigen A6 (MAGEA6), with potential antineoplastic activity. Upon intradermal administration, adenovirus encoding tyrosinase/MART-1/MAGEA6-transduced autologous DC vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tyrosinase/MART-1/MAGEA6-positive tumor cells, which may result in tumor cell death and decreased tumor growth. Tyrosinase, a melanoma-specific differentiation antigen, catalyzes the first step of melanin synthesis in melanocytes. Vaccination with multi-antigen modified DC may improve the efficacy of the DC immunotherapy.
VO:0005488
A cancer vaccine that is developed against cervical cancer.
VO:0005489
A cancer vaccine that is developed against cervical cancer.
VO:0007497
A cancer vaccine containing dendritic cells (DCs) that are transfected with messenger RNA (mRNA) encoding human telomerase reverse transcriptase (hTERT) and survivin in addition to patient-specific melanoma-derived mRNA with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT/survivin/melanoma tumor cell-derived mRNA-transfected dendritic cell vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against melanoma cells expressing hTERT, survivin, and patient-specific melanoma-associated antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival.
VO:0007532
A cancer vaccine containing dendritic cells (DCs) that are transfected with messenger RNA (mRNA) encoding human telomerase reverse transcriptase (hTERT) and survivin in addition to patient-specific melanoma-derived mRNA with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT/survivin/melanoma tumor cell-derived mRNA-transfected dendritic cell vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against melanoma cells expressing hTERT, survivin, and patient-specific melanoma-associated antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival.
VO:0002503
A bacterial gene that is from Streptococcus.
VO:0002504
A bacterial gene that is from Streptococcus.
VO:0001411
A bacterial gene that is from Burkholderia pseudomallei.
VO:0001412
A bacterial gene that is from Burkholderia pseudomallei.
zhengj2007
commented
9 months ago
Following terms shared definitions. Some might be same term need to merge, some seems the annotations were added as definitions by mistake.